FDA clears Teva's generic Trileptal

12/12/2007 | Forbes

Teva Pharmaceutical Industries Ltd. has obtained final FDA approval for its 150-, 300- and 600-milligram oxcarbazepine tablets. The drug is a generic version of Novartis AG's epilepsy drug Trileptal, which reportedly racked up $594 million in sales for the first nine months of 2007. The approval comes amid an unresolved patent dispute between Teva and Novartis over the drug.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC